Evidence map›Paper›PMID 20164449›Full record

ArticleInvestigative ophthalmology & visual science2010

Inhibition of histone deacetylase protects the retina from ischemic injury.

Craig E Crosson, Santhosh K Mani, Shahid Husain, Oday Alsarraf, Donald R Menick

Open access · bronzeAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 103 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Retinoid X receptor agonist 9CDHRA mitigates retinal ganglion cell apoptosis and neuroinflammation in a mouse model of glaucoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Dysregulation of histone deacetylases in ocular diseases.Archives of pharmacal research · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Changes in Class I and IIb HDACs by δ-Opioid in Chronic Rat Glaucoma Model.Investigative ophthalmology & visual science · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Craig E CrossonDepartment of Ophthalmology, Storm Eye Institute, Gazes Cardiac Research Institute, Medical University of South Carolina, Charleston, South Carolina, USA. crossonc@musc.edu
Santhosh K Mani
Shahid Husain
Oday Alsarraf
Donald R Menick
Vision Eye Institute · AU

Funding

ADENOSINE AGONISTS--POTENTIAL ANTIGLAUCOMA DRUGSR01EY009741 · NEI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI CROSSON, CRAIG E. · 1993 to 2010
$3.9M
Role of Protein Acetylation in Ncx1 ExpressionR01HL095696 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MENICK, DONALD R. · 2009 to 2012
$1.5M
Protein Acetylation in Glaucomatous Optic NeuropathyR01EY021368 · NEI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CROSSON, CRAIG E. · 2011 to 2014
$1.4M
NEI NIH HHS EY009741NEI NIH HHS R01 EY009741NEI NIH HHS R01 EY021368NHLBI NIH HHS HL095696NHLBI NIH HHS R01 HL095696
6 · The paper itself

Abstract

PURPOSE. The pathogenesis of retinal ischemia results from a series of events involving changes in gene expression and inflammatory cytokines. Protein acetylation is an essential mechanism in regulating transcriptional and inflammatory events. The purpose of this study was to investigate the neuroprotective action of the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) in a retinal ischemic model. METHODS. To investigate whether HDAC inhibition can reduce ischemic injury, rats were treated with TSA (2.5 mg/kg intraperitoneally) twice daily on days 0, 1, 2, and 3. Seven days after ischemic injury, morphometric and electroretinographic (ERG) analyses were used to assess retinal structure and function. Western blot and immunohistochemical analyses were used to evaluate TSA-induced changes in histone-H3 acetylation and MMP secretion. RESULTS. In vehicle-treated animals, ERG a- and b-waves from ischemic eyes were significantly reduced compared with contralateral responses. In addition, histologic examination of these eyes revealed significant degeneration of inner retinal layers. In rats treated with TSA, amplitudes of ERG a- and b-waves from ischemic eyes were significantly increased, and normal inner retina morphology was preserved. Ischemia also increased the levels of retinal TNF-alpha, which was blocked by TSA treatment. In astrocyte cultures, the addition of TNF-alpha (10 ng/mL) stimulated the secretion of MMP-1 and MMP-3, which were blocked by TSA (100 nM). CONCLUSIONS. These studies provide the first evidence that suppressing HDAC activity can protect the retina from ischemic injury. This neuroprotective response is associated with the suppression of retinal TNF-alpha expression and signaling. The use of HDAC inhibitors may provide a novel treatment for ischemic retinal injury.

Indexed as

AcetylationAnimalsBlotting, WesternElectroretinographyFemaleHistone Deacetylase InhibitorsHistone DeacetylasesHistonesHydroxamic AcidsImmunohistochemistryMaleMatrix Metalloproteinase 1Matrix Metalloproteinase 3Neuroprotective AgentsRatsRats, Inbred BNHistone Deacetylase InhibitorsHistone DeacetylasesHistonesHydroxamic AcidsMatrix Metalloproteinase 1Matrix Metalloproteinase 3Neuroprotective Agentstrichostatin ATumor Necrosis Factor-alpha

Identifiers

PMID20164449
PMCPMC2904015
OpenAlexW2072740129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.